CATALOGO DEI PRODOTTI DELLA RICERCA

PERTILE, Paolo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.543
NA - Nord America 1.479
AS - Asia 587
AF - Africa 13
SA - Sud America 4
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.629
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.472
GB - Regno Unito 483
IT - Italia 360
CN - Cina 352
SG - Singapore 177
RU - Federazione Russa 137
FR - Francia 112
IE - Irlanda 109
SE - Svezia 108
FI - Finlandia 89
DE - Germania 87
UA - Ucraina 19
BE - Belgio 11
VN - Vietnam 11
ID - Indonesia 9
TG - Togo 9
KR - Corea 8
CA - Canada 6
CZ - Repubblica Ceca 6
TR - Turchia 6
HK - Hong Kong 5
IR - Iran 5
AT - Austria 3
DK - Danimarca 3
ES - Italia 3
IN - India 3
PT - Portogallo 3
SY - Repubblica araba siriana 3
UG - Uganda 3
AU - Australia 2
CH - Svizzera 2
CO - Colombia 2
GR - Grecia 2
JO - Giordania 2
JP - Giappone 2
NL - Olanda 2
SA - Arabia Saudita 2
AL - Albania 1
BR - Brasile 1
EC - Ecuador 1
EG - Egitto 1
EU - Europa 1
HU - Ungheria 1
KZ - Kazakistan 1
MT - Malta 1
MX - Messico 1
NO - Norvegia 1
PK - Pakistan 1
Totale 3.629
Salva come PNG Salva come JPEG
Città #
Southend 437
Chandler 308
Woodbridge 198
Jacksonville 162
Ann Arbor 161
Singapore 148
Dublin 109
Ashburn 85
Verona 85
Padova 53
Beijing 51
Princeton 46
Lawrence 44
Wilmington 41
Houston 36
Nanjing 31
Helsinki 29
Milan 28
Shenyang 27
Jinan 24
Tianjin 21
Boardman 16
Hebei 14
Lancaster 14
Zhengzhou 14
Sindelfingen 13
Taiyuan 13
Brussels 11
Haikou 11
Guangzhou 10
Ningbo 10
Dallas 9
Jakarta 9
Lomé 9
Moscow 9
Norwalk 9
Redmond 9
Roverbella 9
Taizhou 9
Hangzhou 8
Jiaxing 8
Los Angeles 8
Afragola 7
Changsha 7
Dong Ket 7
Nanchang 7
New York 7
Belluno 6
Rome 6
Romola 6
Santa Clara 6
Seattle 6
Dearborn 5
Hong Kong 5
Lanzhou 5
San Giovanni Lupatoto 5
Washington 5
Auburn Hills 4
Fairfield 4
Garbagnate Milanese 4
Lonigo 4
Maple 4
Monteforte d'Alpone 4
Redwood City 4
Reggio Calabria 4
Tappahannock 4
Trento 4
Vicenza 4
Braunschweig 3
Falls Church 3
Lungavilla 3
Munich 3
Orani 3
Paese 3
Pisa 3
San Francisco 3
Seoul 3
Vienna 3
Vigo 3
Wuhan 3
Yangcheon-gu 3
Amman 2
Ankara 2
Biebesheim 2
Bogotá 2
Bolzano 2
Brescia 2
Cambridge 2
Chions 2
Clearwater 2
Cologne 2
Copenhagen 2
Dongguan 2
Düsseldorf 2
Esslingen am Neckar 2
Felgueiras 2
Florence 2
Foligno 2
Genoa 2
Hyderabad 2
Totale 2.557
Salva come PNG Salva come JPEG
Nome #
A Large Scale OLG Model for the Analysis of the Redistributive Effects of Policy Reforms 143
Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence 141
Public policies over the life cycle: a large scale OLG model for France, Italy and Sweden 136
R&D and market size: who benefits from orphan drug regulation? 130
Redistribution at the Local Level: The Case of Public Childcare in Italy. University of Verona Department of Economics Working Paper 21/2013 (ISSN 2036-2919) 124
A large scale OLG model for France, Italy and Sweden: assessing the interpersonal and intrapersonal redistributive effects of public policies 112
Redistribution at the Local Level: The Case of Public Childcare in Italy 106
Public finance consolidation and fairness across living generations: the case of Italy. WP Series University of Verona Department of Economics (ISSN 2036-2919), 04/2012 103
L'ISEE in Italia: una nota metodologica partendo dai dati EU-SILC. University of Verona Department of Economics Working Paper 6/2014 (ISSN 2036-2919) 101
The dynamics of pharmaceutical regulation and R&D investments. WP Series University of Verona Department of Economics (ISSN 2036-2919), 4/2012 94
DRGs: the link between investment in technologies and appropriateness. WP Series University of Verona Department of Economics (ISSN 2036-2919), 31/2012 87
Late-Stage Pharmaceutical R&D and Pricing Policies under Two-Stage Regulation 87
A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response 82
Dynamic, economic approaches to HTA under uncertainty. WP Series University of Verona Department of Economics (ISSN 2036-2919), 03/2011 81
The dynamics of pharmaceutical regulation and R&D investments 81
Optimal Decision Rules for HTA Under Uncertainty: a Wider, Dynamic Perspective 79
Who should monitor job sick leave? 79
Two-part payments for the reimbursement of investments in health technologies 76
Should current criteria for detecting and repairing arteriovenous fistula stenosis be reconsidered? Interim analysis of a randomized controlled trial 76
Drug Prices and Incentives to Innovation by the Pharmaceutical Industry 75
Late-Stage Pharmaceutical R&D and Pricing Policies under Two-Stage Regulation 74
The fiscal disadvantage of young italians: a new view on consolidation and fairness 73
The timing of adoption of positron emission tomography:a real options approach 73
Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies 72
Job Sick Leave: Detecting Opportunistic Behavior 72
Optimal sequential sampling rules for the economic evaluation of health technologies 71
Spillovers of Pharmaceutical Price Regulations: evidence from the AMNOG Reform in Germany 69
Technology adoption, quality and health care costs: a review of the literature 68
An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography 68
A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response 68
Pricing policies when patients are heterogeneous: a welfare analysis 68
Investment in health technologies in a competitive model with real options 67
Is chest X-ray screening for lung cancer in smokers cost-effective? Evidence from a population-based study in Italy 62
Static and dynamic effciency of irreversible health care investments under alternative payment rules 61
The impact of managed entry agreements on pharmaceutical prices 59
R&D and market size: who benefits from orphan drug legislation? 58
L’equità intergenerazionale delle politiche di bilancio 57
Public health interventions: evaluating the economic evaluations 57
A reply to "Who would benefit from average value-based pricing?" 57
Static and Dynamic Efficiency of Irreversible Health Care investments under Alternative Payment Rules 53
Cost-effective clinical trial design: Application of a Bayesian sequential model to the ProFHER pragmatic trial 47
Authors' Reply to Garattini and Freemantle: "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition" 45
Optimal Sequential Sampling with Delayed Observations and Unknown Variance 45
Efficienza e sostenibilità dell’intervento pubblico 42
Improving access to medicines and promoting pharmaceutical innovation 36
Which valued-based price when patients are heterogeneous? 35
Investimenti pubblici, risorse scarse: il ruolo dei diversi metodi di supporto alle decisioni 34
Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition 30
A stepped-wedge randomised controlled trial to assess efficacy and cost-effectiveness of a care-bundle to prevent falls in older hospitalised patients 26
Valutare l’efficienza dei servizi ospedalieri in Italia: il caso delle aziende ospedaliero-universitarie 23
Dynamic, incentive-compatible contracting for health services 20
Strategic Interaction in Pharmaceutical Price Regulation: With or Without U? 19
Totale 3.702
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.399
article - articoli 6.931
book - libri 0
conference - conferenze 231
curatela - curatele 221
other - altro 5.177
patent - brevetti 0
selected - selezionate 0
volume - volumi 839
Totale 26.798
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020220 0 0 0 0 19 30 70 15 7 35 16 28
2020/2021372 48 69 10 51 40 32 6 18 40 13 26 19
2021/2022422 30 70 13 6 19 17 18 25 41 13 66 104
2022/2023804 60 96 72 122 76 194 7 53 84 12 24 4
2023/2024435 18 30 31 72 47 57 27 38 10 16 53 36
2024/2025436 57 90 67 195 27 0 0 0 0 0 0 0
Totale 3.702